Evidence map›Paper›PMID 40545248›Full record

Observational studyBritish journal of clinical pharmacology2025

Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients.

Jaap W A Mouton, Julian D Machiels, Arthur M A Pistorius, Rob Ter Heine, Tim Frenzel, Nynke G L Jager, Jeroen A Schouten, Paddy K C Janssen, Rob E Aarnoutse, Roger J Brüggemann

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jaap W A MoutonDepartment of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.ORCID https://orcid.org/0009-0005-3925-9161
Julian D MachielsDepartment of Medical Microbiology, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-2606-8276
Arthur M A PistoriusDepartment of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-1865-4961
Rob Ter HeineDepartment of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-2185-8201
Tim FrenzelDepartment of Intensive Care, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0003-3988-7131
Nynke G L JagerDepartment of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-4524-9892
Jeroen A SchoutenDepartment of Intensive Care, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0001-9118-4420
Paddy K C JanssenDepartment of Hospital Pharmacy, VieCuri Medical Center, Venlo, The Netherlands.ORCID https://orcid.org/0000-0002-3050-2728
Rob E AarnoutseDepartment of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.
Roger J BrüggemannDepartment of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0002-7618-725X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cefuroxime is a second-generation cephalosporin widely used in the intensive care unit (ICU). ICU patients have high variability in interpatient pharmacokinetics (PK), but the extent of this variation is unclear. We performed an observational PK study in ICU patients. The objective of this study was to gain knowledge on the PK of cefuroxime and investigate target attainment of currently clinically applied dosing regimens. To identify the most suitable regimen the time above the minimal inhibitory concentration of the unbound drug (%fT > MIC) was calculated for different minimal inhibitory concentrations (MICs) and estimated Glomerular Filtration rates (eGFRs). Twenty patients were included with an average age of 66 years and modification of diet in renal disease (MDRD) (not indexed by BSA) of 90 [60-117.5] mL/min. A two-compartment model best fitted the data, with eGFR as a covariate. Probability of target attainment (PTA) was 43% for a 1500-mg q8h bolus dosage for the EUCAST break point of 8 mg/L for a typical individual with a eGFR of 60 mL/min. Dosing continuously using 4.5 g/day obtained 100% PTA for a typical individual with a eGFR up to 120 mL/min.

Indexed as

Anti-Bacterial AgentsCefuroximeCritical IllnessAgedAged, 80 and overDose-Response Relationship, DrugFemaleGlomerular Filtration RateHumansIntensive Care UnitsMaleMicrobial Sensitivity TestsMiddle AgedModels, BiologicalAnti-Bacterial AgentsCefuroximeantibioticscritical care medicineICUintensive carePK/PDsimulation

Identifiers

PMID40545248
PMCPMC12381626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.